{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:chemidarou-industrial-company",
    "identifier": "hg:company:chemidarou-industrial-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:17+00:00",
    "name": "Chemidarou Industrial Company",
    "slug": "chemidarou-industrial-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/chemidarou-industrial-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/chemidarou-industrial-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/chemidarou-industrial-company",
    "summary": "",
    "machine_summary": "Chemidarou Industrial Company Chemidarou Industrial Company is a listed Tehran-based pharmaceutical manufacturer with a long operating history and a broad product portfolio across common therapeutic classes. In the Hormuz Group company graph, it matters because it connects domestic medicine manufacturing, raw-material imports, regulated pricing, pharmacy demand, distribution networks, and healthcare supply stability. Its listed status makes it useful for monitoring pharmaceutical margins, product mix, disclosure quality, and exposure to imported active ingredients. Chemidarou is relevant for investors assessing Iran's listed pharmaceutical sector, domestic drug production, therapeutic diversification, import dependence for APIs and excipients, and pricing regulation. It can support analysis of medicine shortages, production resilience, distributor payment cycles, regulatory reimbursement, and the ability of local manufacturers to substitute imported finished drugs. Due diligence should review current financial disclosures, product registrations, GMP status, raw-material sourcing, export channels, energy and packaging costs, receivables, and shareholder or holding-company relationships. Chemidarou Industrial Company manufactures pharmaceutical products in forms including ampoules, tablets, capsules, drops, suspensions, and supplements. Its therapeutic coverage includes painkillers, cardiovascular, anti-diabetic, anti-fungal, digestive, antibiotic, antihistamine, rheumatology, anti-gout, urology, neuropsychiatric, and food-supplement categories. province: Tehran industry: Chemicals, Healthcare & Pharma, Pharmaceuticals market: Consumer Demand, Healthcare, Materials, Supply Chains challenges: Compliance, Import Dependence, Supply Shortage, Technology Gap company_type: Manufacturer city: Tehran",
    "published_at": "2026-06-28T20:21:36+00:00",
    "modified_at": "2026-06-28T20:21:36+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 3,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/provinces/tehran/"
            }
        ],
        "industry": [
            {
                "id": 95,
                "name": "Chemicals",
                "slug": "chemicals",
                "url": "https://hormuz.group/industry/manufacturing/chemicals/"
            },
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 34,
                "name": "Consumer Demand",
                "slug": "consumer-demand",
                "url": "https://hormuz.group/market/consumer-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 73,
                "name": "Materials",
                "slug": "materials",
                "url": "https://hormuz.group/market/enterprise-demand/materials/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 177,
                "name": "Supply Shortage",
                "slug": "supply-shortage",
                "url": "https://hormuz.group/challenges/market-gaps/supply-shortage/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 299,
                "name": "Manufacturer",
                "slug": "manufacturer",
                "url": "https://hormuz.group/company-type/manufacturer/"
            }
        ],
        "city": [
            {
                "id": 384,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/cities/tehran/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "Tehran",
        "industry": "Chemicals, Healthcare & Pharma, Pharmaceuticals",
        "market": "Consumer Demand, Healthcare, Materials, Supply Chains",
        "challenges": "Compliance, Import Dependence, Supply Shortage, Technology Gap",
        "company_type": "Manufacturer",
        "city": "Tehran"
    },
    "fields_summary": {
        "legal_name": "Chemi Darou Industrial Company Public Joint Stock Company",
        "website": "https://www.chemidarou.com",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "دکیمی",
        "listing_status": "listed_tse",
        "products_services": "Chemidarou Industrial Company manufactures pharmaceutical products in forms including ampoules, tablets, capsules, drops, suspensions, and supplements. Its therapeutic coverage includes painkillers, cardiovascular, anti-diabetic, anti-fungal, digestive, antibiotic, antihistamine, rheumatology, anti-gout, urology, neuropsychiatric, and food-supplement categories.",
        "export_relevance": "medium",
        "short_profile": "Chemidarou Industrial Company is a listed Tehran-based pharmaceutical manufacturer with a long operating history and a broad product portfolio across common therapeutic classes. In the Hormuz Group company graph, it matters because it connects domestic medicine manufacturing, raw-material imports, regulated pricing, pharmacy demand, distribution networks, and healthcare supply stability. Its listed status makes it useful for monitoring pharmaceutical margins, product mix, disclosure quality, and exposure to imported active ingredients.",
        "investment_relevance": "Chemidarou is relevant for investors assessing Iran's listed pharmaceutical sector, domestic drug production, therapeutic diversification, import dependence for APIs and excipients, and pricing regulation. It can support analysis of medicine shortages, production resilience, distributor payment cycles, regulatory reimbursement, and the ability of local manufacturers to substitute imported finished drugs. Due diligence should review current financial disclosures, product registrations, GMP status, raw-material sourcing, export channels, energy and packaging costs, receivables, and shareholder or holding-company relationships."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "Chemi Darou Industrial Company Public Joint Stock Company",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "دکیمی",
        "export_relevance": "medium",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "listed_tse",
        "last_updated": "28/06/2026",
        "website": "https://www.chemidarou.com",
        "products_services": "Chemidarou Industrial Company manufactures pharmaceutical products in forms including ampoules, tablets, capsules, drops, suspensions, and supplements. Its therapeutic coverage includes painkillers, cardiovascular, anti-diabetic, anti-fungal, digestive, antibiotic, antihistamine, rheumatology, anti-gout, urology, neuropsychiatric, and food-supplement categories.",
        "short_profile": "Chemidarou Industrial Company is a listed Tehran-based pharmaceutical manufacturer with a long operating history and a broad product portfolio across common therapeutic classes. In the Hormuz Group company graph, it matters because it connects domestic medicine manufacturing, raw-material imports, regulated pricing, pharmacy demand, distribution networks, and healthcare supply stability. Its listed status makes it useful for monitoring pharmaceutical margins, product mix, disclosure quality, and exposure to imported active ingredients.",
        "investment_relevance": "Chemidarou is relevant for investors assessing Iran's listed pharmaceutical sector, domestic drug production, therapeutic diversification, import dependence for APIs and excipients, and pricing regulation. It can support analysis of medicine shortages, production resilience, distributor payment cycles, regulatory reimbursement, and the ability of local manufacturers to substitute imported finished drugs. Due diligence should review current financial disclosures, product registrations, GMP status, raw-material sourcing, export channels, energy and packaging costs, receivables, and shareholder or holding-company relationships.",
        "source_note": "Based on public company, official-company, pharmaceutical-sector, market, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 57
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 29
        },
        "ticker_symbol": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 6
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 26
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 364
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 541
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 632
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 208
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, official-company, pharmaceutical-sector, market, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "28/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "28/06/2026"
    }
}